Molecular signatures define alopecia areata subtypes and transcriptional biomarkers

EBioMedicine

Volumn 7, Issue , 2016, Pages 240-247

  Jabbari, Ali ^a   Cerise, Jane E ^a   Chen, James C ^a   Mackay Wiggan, Julian ^a   Duvic, Madeleine ^b   Price, Vera ^c   Hordinsky, Maria ^d   Norris, David ^e   Clynes, Raphael ^a   Christiano, Angela M ^a  

^a Columbia University ^*  (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Alopecia areata; Autoimmune; Biomarkers

Indexed keywords

BIOLOGICAL MARKER; INTERFERON; KERATIN; GENETIC MARKER;

ALOPECIA AREATA; ALOPECIA AREATA DISEASE ACTIVITY INDEX; ARTICLE; ASSESSMENT OF HUMANS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE SEVERITY; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; LYMPHOCYTIC INFILTRATION; MICROARRAY ANALYSIS; PATHOGENESIS; PHENOTYPE; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; TH1 TH2 BALANCE; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENETIC DATABASE; GENETIC MARKER; GENETICS; IMMUNOLOGY; PATHOLOGY; PROCEDURES;

ALOPECIA AREATA; DATABASES, GENETIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC MARKERS; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PRINCIPAL COMPONENT ANALYSIS;

EID: 84964583070     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2016.03.036     Document Type: Article

References (27)

1. Alkhalifah A., Alsantali A., Wang E., McElwee K.J., Shapiro J. Alopecia areata update: part II. Treatment. J. Am. Acad. Dermatol. 2010, 62:191-202. (quiz 203-4). 10.1016/j.jaad.2009.10.031.
2. Bertolini M., Zilio F., Rossi A., Kleditzsch P., Emelianov V.E., et al. Abnormal interactions between perifollicular mast cells and CD8+ T-cells may contribute to the pathogenesis of alopecia areata. PLoS ONE 2014, 9:e94260. 10.1371/journal.pone.0094260.
3. Betz R.C., Petukhova L., Ripke S., Huang H., Menelaou A., et al. Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci. Nat. Commun. 2015, 6:5966. 10.1038/ncomms6966.
4. Bindea G., Mlecnik B., Tosolini M., Kirilovsky A., Waldner M., et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013, 39:782-795. 10.1016/j.immuni.2013.10.003.
5. Carroll J.M., McElwee K.J., E King L., Byrne M.C., Sundberg J.P. Gene array profiling and immunomodulation studies define a cell-mediated immune response underlying the pathogenesis of alopecia areata in a mouse model and humans. J. Investig. Dermatol. 2002, 119:392-402. 10.1046/j.1523-1747.2002.01811.x.
6. Castellana D., Paus R., Perez-Moreno M. Macrophages contribute to the cyclic activation of adult hair follicle stem cells. PLoS Biol. 2014, 12:e1002002. 10.1371/journal.pbio.1002002.
7. Chen J.C., Cerise J.E., Jabbari A., Clynes R., Christiano A.M. Master regulators of infiltrate recruitment in autoimmune disease identified through network-based molecular deconvolution. Cell Syst. 2015, 1(5):326-337.
8. Claudy A.L., Gagnaire D. PUVA treatment of alopecia areata. Arch. Dermatol. 1983, 119:975-978.
9. Craiglow B.G., King B.A. Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J. Investig. Dermatol. 2014, 134:2988-2990. 10.1038/jid.2014.260.
10. Elston D.M., McCollough M.L., Bergfeld W.F., Liranzo M.O., Heibel M. Eosinophils in fibrous tracts and near hair bulbs: a helpful diagnostic feature of alopecia areata. J. Am. Acad. Dermatol. 1997, 37:101-106.
11. Gilhar A., Etzioni A., Paus R. Alopecia Areata. N. Engl. J. Med. 2012, 366:1515-1525. 10.1056/NEJMra1103442.
12. Gregersen P.K., Olsson L.M. Recent advances in the genetics of autoimmune disease. Annu. Rev. Immunol. 2009, 27:363-391. 10.1146/annurev.immunol.021908.132653.
13. Higgins E., Shehri Al T., McAleer M.A., Conlon N., Feighery C., et al. Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation. J. Allergy Clin. Immunol. 2015, 135:551-553.e3. 10.1016/j.jaci.2014.12.1867.
14. Ito T., Ito N., Saatoff M., Hashizume H., Fukamizu H., et al. Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack. J. Investig. Dermatol. 2008, 128:1196-1206. 10.1038/sj.jid.5701183.
15. Ito T., Aoshima M., Ito N., Uchiyama I., Sakamoto K., et al. Combination therapy with oral PUVA and corticosteroid for recalcitrant alopecia areata. Arch. Dermatol. Res. 2009, 301:373-380. 10.1007/s00403-009-0936-8.
16. Jabbari A., Dai Z., Xing L., Cerise J.E., Ramot Y., et al. Reversal of alopecia areata following treatment with the JAK1/2 inhibitor baricitinib. EBioMedicine 2015, 2:351-355. 10.1016/j.ebiom.2015.02.015.
17. Kaufman G., d'Ovidio R., Kaldawy A., Assy B., Ullmann Y., et al. An unexpected twist in alopecia areata pathogenesis: are NK cells protective and CD49b+ T cells pathogenic?. Exp. Dermatol. 2010, 19:e347-e349. 10.1111/j.1600-0625.2010.01106.x.
18. McElwee K.J., Freyschmidt-Paul P., Hoffmann R., Kissling S., Hummel S., et al. Transfer of CD8(+) cells induces localized hair loss whereas CD4(+)/CD25(-) cells promote systemic alopecia areata and CD4(+)/CD25(+) cells blockade disease onset in the C3H/HeJ mouse model. J. Investig. Dermatol. 2005, 124:947-957. 10.1111/j.0022-202X.2005.23692.x.
19. Petukhova L., Duvic M., Hordinsky M., Norris D., Price V., et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature 2010, 466:113-117. 10.1038/nature09114.
20. Pieri L., Guglielmelli P., Vannucchi A.M. Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia. Am. J. Hematol. 2015, 90:82-83. 10.1002/ajh.23871.
21. Rashighi M., Agarwal P., Richmond J.M., Harris T.H., Dresser K., et al. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci. Transl. Med. 2014, 6. (223ra23-223ra23). 10.1126/scitranslmed.3007811.
22. Smyth G.K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 2004, 3. (Article3). 10.2202/1544-6115.1027.
23. Suárez-Fariñas M., Ungar B., Noda S., Shroff A., Mansouri Y., et al. Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17/TH22 skewing. J. Allergy Clin. Immunol. 2015, 136:1277-1287. 10.1016/j.jaci.2015.06.032.
24. Subramanya R.D., Coda A.B., Sinha A.A. Transcriptional profiling in alopecia areata defines immune and cell cycle control related genes within disease-specific signatures. Genomics 2010, 96:146-153. 10.1016/j.ygeno.2010.05.002.
25. Whiting D.A. Histopathologic features of alopecia areata: a new look. Arch. Dermatol. 2003, 139:1555-1559. 10.1001/archderm.139.12.1555.
26. Whiting D.A. Histopathologic features of alopecia areata. Arch. Dermatol. 2003, 139:1555-1559. 10.1001/archderm.139.12.1555.
27. Xing L., Dai Z., Jabbari A., Cerise J.E., Higgins C.A., et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat. Med. 2014, 20:1043-1049. 10.1038/nm.3645.